Bottoni, Patrizia
 Distribuzione geografica
Continente #
NA - Nord America 1.556
EU - Europa 1.228
AS - Asia 688
SA - Sud America 88
AF - Africa 11
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.576
Nazione #
US - Stati Uniti d'America 1.528
DE - Germania 387
CN - Cina 309
UA - Ucraina 202
SE - Svezia 200
SG - Singapore 190
IT - Italia 88
BR - Brasile 81
IE - Irlanda 71
FR - Francia 57
FI - Finlandia 52
GB - Regno Unito 48
TR - Turchia 48
ID - Indonesia 42
RU - Federazione Russa 41
IN - India 35
CA - Canada 26
BE - Belgio 16
ES - Italia 14
KR - Corea 14
JP - Giappone 11
NL - Olanda 11
CH - Svizzera 8
VN - Vietnam 6
CZ - Repubblica Ceca 5
HK - Hong Kong 5
IQ - Iraq 5
RO - Romania 5
ZA - Sudafrica 5
IR - Iran 4
VE - Venezuela 4
DK - Danimarca 3
IL - Israele 3
MA - Marocco 3
MY - Malesia 3
PK - Pakistan 3
PT - Portogallo 3
AT - Austria 2
AU - Australia 2
BD - Bangladesh 2
HU - Ungheria 2
LU - Lussemburgo 2
MX - Messico 2
NO - Norvegia 2
PL - Polonia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
CL - Cile 1
DZ - Algeria 1
EG - Egitto 1
EU - Europa 1
GE - Georgia 1
HR - Croazia 1
KG - Kirghizistan 1
LT - Lituania 1
LV - Lettonia 1
ME - Montenegro 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 3.576
Città #
Chandler 294
Singapore 120
Jacksonville 103
San Mateo 76
Nanjing 72
Ashburn 71
Dublin 67
New York 56
Wilmington 48
Ann Arbor 46
Redmond 43
Izmir 42
Woodbridge 40
Jakarta 39
The Dalles 38
Dearborn 37
Beijing 33
Houston 33
Lawrence 30
Boston 28
Bremen 24
Chicago 24
Moscow 23
Cattolica 21
Fairfield 20
Detroit 18
Seattle 18
Boardman 16
Kunming 16
Los Angeles 16
Mountain View 15
Nanchang 15
Nürnberg 14
Zhengzhou 14
Redwood City 13
Shanghai 13
Brussels 12
Helsinki 12
Montreal 12
Hangzhou 11
Hebei 11
Rome 11
Philadelphia 10
Shenyang 10
Hefei 9
Princeton 9
Seoul 9
Frankfurt am Main 8
Guangzhou 8
Pune 8
University Park 8
Düsseldorf 7
Lancaster 7
Milan 7
Belo Horizonte 6
Cambridge 6
Chengdu 6
Edinburgh 6
London 6
Madrid 6
São Paulo 6
Tianjin 6
Toronto 6
Indiana 5
Jiaxing 5
Simi Valley 5
Zurich 5
Changsha 4
Hong Kong 4
Johannesburg 4
Lansing 4
Lanzhou 4
Littleton 4
Marseille 4
Norwalk 4
Ottawa 4
Portsmouth 4
Bern 3
Brasília 3
Brea 3
Brooklyn 3
Busto Arsizio 3
Centrale 3
Council Bluffs 3
Curitiba 3
Erlangen 3
Falls Church 3
Guidonia 3
Lauterbourg 3
Leawood 3
Lindewitt 3
Menlo Park 3
Najaf 3
Prague 3
San Francisco 3
Santa Clara 3
Vigo 3
Ancona 2
Atlanta 2
Augusta 2
Totale 1.945
Nome #
Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects 162
CA 19-9: Biochemical and Clinical Aspects 141
MITOCHONDRIAL DAMAGE AND METABOLIC COMPENSATORY MECHANISMS INDUCED BY HYPEROXIA IN U-937 CELL LINE. 128
3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds Through Structure-Based Drug Design and Docking Studies 127
Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. 120
Neuron Specific Enolase as a biomarker: biochemical and clinical aspects 119
A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line 113
A Critical Approach to Clinical Biochemistry of Chromogranin A 112
An update on pharmacological approaches to neurodegenerative diseases. 108
Mitochondrial proteomic approaches for new potential diagnostic and prognostic biomarkers in cancer 107
A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists. 106
The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects 106
Advances in Mitochondrial Medicine 104
3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole C2 and/or C4 Substitutions on Biological Activity 104
Bezafibrate Induces a Mitochondrial Derangement in Human Cell Lines. Intriguing Effects for a Peroxisome Proliferator. 102
The epithelial–mesenchymal transition in cancer: a potential critical topic for translational proteomic research 102
CA 19-9: Biochemical and Clinical Aspects 102
The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. 98
Circulating tumour cells and cancer stem cells: A role for proteomics in defining the interrelationships between function,phenotype and differentiation with potential clinical applications. 96
Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy 93
A critical approach to clinical biochemistry of Chromogranin A 91
Modulation of cancer cell line differentiation: A neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. 89
Cancer Stem Cells: An Innovative Therapeutic Approach 86
Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. 84
Cancer stem cells: the development of new cancer therapeutics 81
The proteomics of cancer stem cells. Potential clinical applications for innovative research in oncology 80
The role of CA 125 as tumor marker: biochemical and clinical aspects 78
CA 19-9: Biochemical and Clinical Aspects 78
Mitochondrial respiration and differentiation 75
Proteomic profiling of heat shock proteins: An emerging molecular approach with direct pathophysiological and clinical implications 74
Cancer Stem Cells: Proteomic Approaches for New Potential Diagnostic and Prognostic Biomarkers 73
Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks. 72
Advances in Heat Shock Proteomics: Towards a Better Understanding of the Physiology and Pathophysiology of Molecular Chaperones. 71
Glycolytic enzyme inhibitors in cancer treatment. 66
Cellular respiration and dedifferentiation 65
Aroyl-Pyrrolyl Hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetilase inhibition 60
Aroyl-pyrrolyl hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetylase inhibition. 49
Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. 43
Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key? 39
Totale 3.604
Categoria #
all - tutte 14.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.573


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202092 0 0 0 0 0 0 0 0 0 0 46 46
2020/2021349 16 38 12 38 40 36 36 3 50 7 64 9
2021/2022343 29 39 4 39 21 16 8 56 8 17 37 69
2022/2023792 100 107 60 124 78 91 13 77 81 20 33 8
2023/2024319 19 95 4 7 12 62 13 13 4 13 45 32
2024/2025579 22 17 51 26 70 25 19 50 99 86 114 0
Totale 3.604